AARD earnings
Aardvark Therapeutics Inc. (AARD) earnings releases and earnings dates - real-time wire coverage of every quarterly report.
Recent earnings items
- Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension TrialsHERO trial terminated early (67 of 90 planned participants randomized); all efficacy data are considered exploratoryHQ-CT scores fell by Week 2 of dose escalation on ARD-101 and returned to near baseline within two weeks of stopping treatment, with less rebound on placeboOLE participants switching from placebo to ARD-101 saw a further reduction in HQ-CT scores by Day 28ARD-101 was well tolerated; most adverse events mild to moderateFDA lifted full clinical hold on ARD-101; Company plans to request FDA meeting to align on new Phase 3 trial design and expects to resume PWS clinical activities in 2027Conference call and webcast today at 8:00 a.m. ET SAN DIEGO, Oct. 23, 2026 (GLOBE NEWSWIRE)
- Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE DataClinical development of ARD-101 for hyperphagia in Prader-Willi Syndrome (PWS) may resume Aardvark will host a webcast to review available dataset from the terminated Phase 3 HERO trial and OLE trial on Friday, October 23, 2026, at 8:00 a.m. EST SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (NASDAQ:AARD), a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi Syndrome (PWS) and metabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company’s Investigational New Drug applicatio